Background:Stool-based molecular markers have shown potential as a strategy for colorectal cancer(CRC)screening.This study aimed to evaluate the feasibility of using microRNA-92a expression as a biomarker for CRC in s...Background:Stool-based molecular markers have shown potential as a strategy for colorectal cancer(CRC)screening.This study aimed to evaluate the feasibility of using microRNA-92a expression as a biomarker for CRC in stool samples.Methods:The level of microRNA-92a was measured in stool samples from 210 CRC patients,29 patients with advanced adenomas,15 patients with other cancers,and 101 healthy controls,using real-time quantitative polymerase chain reaction.Receiver operating characteristic curves were used to evaluate sensitivity and specificity.Results:MicroRNA-92a expression was positive in 70.1%of CRC patients,44.8%of advanced adenomas patients,and 36.6%of healthy controls,using a cut-off value of 31.5.The corresponding sensitivity and specificity for discriminating CRC from advanced adenomas were 66.9%and 63.4%,respectively.Moreover,stool-based microRNA-92a expression was better at detecting CRC cancers in the distal colon(sensitivity 82.1%)than the proximal colon(sensitivity 67.9%).There were no significant differences in clinical stage of CRC when comparing AUCs of each parameter(P>0.05).Conclusion:These findings suggest that microRNA-92a expression in stool samples could serve as a promising non-invasive biomarker for CRC detection.展开更多
Colorectal cancer(CRC)has high incidence and mortality rates,and the em-ergence and application of CRC screening have helped us effectively control the occurrence and development of CRC.Currently,common international ...Colorectal cancer(CRC)has high incidence and mortality rates,and the em-ergence and application of CRC screening have helped us effectively control the occurrence and development of CRC.Currently,common international screening methods include tests based on feces and blood,and examination methods that allow for visualization,such as sigmoidoscopy and colonoscopy.Some methods have been widely used,whereas others such as multi-target stool RNA test are still being explored and developed,and are expected to become front-line screening methods for CRC in the future.The choice of screening method is affected by external conditions and the patients'situation,and the clinician must choose an appropriate strategy according to the actual situation and the patient's wishes.This article introduces various CRC screening methods and analyzes the factors relevant to the screening strategy.展开更多
Background:Colorectal cancer(CRC)is the third-most-common malignancy and the second-leading cause of cancer-related deaths worldwide and current screening methods such as guaiac-based fecal occult blood test(gFOBT),fe...Background:Colorectal cancer(CRC)is the third-most-common malignancy and the second-leading cause of cancer-related deaths worldwide and current screening methods such as guaiac-based fecal occult blood test(gFOBT),fecal immunochemical test(FIT),and colonoscopy have their own pros and cons.This study aimed to assess the effectiveness of a fecal DNA methylation test by using methylated SDC2(mSDC2)as the epigenetic biomarker for detecting CRC in a screening-naïve population.Methods:Fecal mSDC2 test and FIT were simultaneously performed on eligible 40-to 74-year-old adults of a regional township in China.Subjects with positive results were recommended for colonoscopy.Data of positivity rates,positive predicted values(PPVs),and detection rates associated with clinical characteristics were analysed.Results:The positivity rate of mSDC2 was 7.6%for 10,578 participants with valid results from both fecal mSDC2 test and FIT.With an adherence rate of 63.8%to colonoscopy referral,25 CRCs,189 advanced adenomas(AAs),and 165 non-advanced adenomas(NAAs)and polyps were detected.The PPVs of mSDC2 were 4.93%,37.28%,and 32.54%for CRC,AA,and non-advanced lesions,respectively.When the CRCs and AAs were counted as positive findings,the fecal mSDC2 test showed a higher detective rate than FIT(relative risk[RR],1.313[1.129-1.528],P<0.001).When NAAs and polyps were also specified as treatable lesions,the mSDC2 test was more effective in detecting these benign growths(RR,1.872[1.419-2.410];P<0.001).A combination of mSDC2 and FIT detected 29 CRCs,298 AAs,and 234 NAAs and polyps.Overall,the fecal mSDC2 test had a higher detection rate for both advanced and non-advanced colonic lesions.The false-positive rate of the fecal mSDC2 test was comparable to that of FIT(RR,1.169[0.974-1.403];P=0.113).Conclusions:The single-target stool-based mSDC2 test can effectively and accurately detect CRC and precancerous lesions in a large-scale CRC-screening program.Trial registration number:NCT05374369.展开更多
基金This study was supported by the National Natural Science Foundation of China(Grant No.82202907 to Rong-Bin Liu).
文摘Background:Stool-based molecular markers have shown potential as a strategy for colorectal cancer(CRC)screening.This study aimed to evaluate the feasibility of using microRNA-92a expression as a biomarker for CRC in stool samples.Methods:The level of microRNA-92a was measured in stool samples from 210 CRC patients,29 patients with advanced adenomas,15 patients with other cancers,and 101 healthy controls,using real-time quantitative polymerase chain reaction.Receiver operating characteristic curves were used to evaluate sensitivity and specificity.Results:MicroRNA-92a expression was positive in 70.1%of CRC patients,44.8%of advanced adenomas patients,and 36.6%of healthy controls,using a cut-off value of 31.5.The corresponding sensitivity and specificity for discriminating CRC from advanced adenomas were 66.9%and 63.4%,respectively.Moreover,stool-based microRNA-92a expression was better at detecting CRC cancers in the distal colon(sensitivity 82.1%)than the proximal colon(sensitivity 67.9%).There were no significant differences in clinical stage of CRC when comparing AUCs of each parameter(P>0.05).Conclusion:These findings suggest that microRNA-92a expression in stool samples could serve as a promising non-invasive biomarker for CRC detection.
基金Supported by Liaoning Province Applied Basic Research Program Joint Program Project,No.2022JH2/101500076Shenyang Young and Middle-aged Science and Technology Innovation Talent Support Program,No.RC200438Tree Planting Program of Shengjing Hospital,No.M1595.
文摘Colorectal cancer(CRC)has high incidence and mortality rates,and the em-ergence and application of CRC screening have helped us effectively control the occurrence and development of CRC.Currently,common international screening methods include tests based on feces and blood,and examination methods that allow for visualization,such as sigmoidoscopy and colonoscopy.Some methods have been widely used,whereas others such as multi-target stool RNA test are still being explored and developed,and are expected to become front-line screening methods for CRC in the future.The choice of screening method is affected by external conditions and the patients'situation,and the clinician must choose an appropriate strategy according to the actual situation and the patient's wishes.This article introduces various CRC screening methods and analyzes the factors relevant to the screening strategy.
基金supported by the National Key Research and Development Program of China[2017YFC1308800 to H.Z.]and the Talent Project of Innovation and Entrepreneurship in Developmental Zone of Guangzhou[Grant No.2017-L1772022-L025 to H.Z.].
文摘Background:Colorectal cancer(CRC)is the third-most-common malignancy and the second-leading cause of cancer-related deaths worldwide and current screening methods such as guaiac-based fecal occult blood test(gFOBT),fecal immunochemical test(FIT),and colonoscopy have their own pros and cons.This study aimed to assess the effectiveness of a fecal DNA methylation test by using methylated SDC2(mSDC2)as the epigenetic biomarker for detecting CRC in a screening-naïve population.Methods:Fecal mSDC2 test and FIT were simultaneously performed on eligible 40-to 74-year-old adults of a regional township in China.Subjects with positive results were recommended for colonoscopy.Data of positivity rates,positive predicted values(PPVs),and detection rates associated with clinical characteristics were analysed.Results:The positivity rate of mSDC2 was 7.6%for 10,578 participants with valid results from both fecal mSDC2 test and FIT.With an adherence rate of 63.8%to colonoscopy referral,25 CRCs,189 advanced adenomas(AAs),and 165 non-advanced adenomas(NAAs)and polyps were detected.The PPVs of mSDC2 were 4.93%,37.28%,and 32.54%for CRC,AA,and non-advanced lesions,respectively.When the CRCs and AAs were counted as positive findings,the fecal mSDC2 test showed a higher detective rate than FIT(relative risk[RR],1.313[1.129-1.528],P<0.001).When NAAs and polyps were also specified as treatable lesions,the mSDC2 test was more effective in detecting these benign growths(RR,1.872[1.419-2.410];P<0.001).A combination of mSDC2 and FIT detected 29 CRCs,298 AAs,and 234 NAAs and polyps.Overall,the fecal mSDC2 test had a higher detection rate for both advanced and non-advanced colonic lesions.The false-positive rate of the fecal mSDC2 test was comparable to that of FIT(RR,1.169[0.974-1.403];P=0.113).Conclusions:The single-target stool-based mSDC2 test can effectively and accurately detect CRC and precancerous lesions in a large-scale CRC-screening program.Trial registration number:NCT05374369.
